Logo image of QURE

UNIQURE NV (QURE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:QURE - NL0010696654 - Common Stock

22.31 USD
-0.32 (-1.41%)
Last: 1/6/2026, 8:00:01 PM
22.75 USD
+0.44 (+1.97%)
After Hours: 1/6/2026, 8:00:01 PM
Fundamental Rating

3

QURE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. QURE may be in some trouble as it scores bad on both profitability and health. QURE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

QURE had negative earnings in the past year.
In the past year QURE has reported a negative cash flow from operations.
QURE had negative earnings in 4 of the past 5 years.
In the past 5 years QURE reported 4 times negative operating cash flow.
QURE Yearly Net Income VS EBIT VS OCF VS FCFQURE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -26.47%, QURE is in the better half of the industry, outperforming 70.00% of the companies in the same industry.
Looking at the Return On Equity, with a value of -102.80%, QURE is in line with its industry, outperforming 45.66% of the companies in the same industry.
Industry RankSector Rank
ROA -26.47%
ROE -102.8%
ROIC N/A
ROA(3y)-32.71%
ROA(5y)-18.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QURE Yearly ROA, ROE, ROICQURE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

QURE has a better Gross Margin (88.13%) than 90.19% of its industry peers.
In the last couple of years the Gross Margin of QURE has declined.
The Profit Margin and Operating Margin are not available for QURE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.17%
GM growth 5YN/A
QURE Yearly Profit, Operating, Gross MarginsQURE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

QURE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for QURE has been increased compared to 1 year ago.
Compared to 5 years ago, QURE has more shares outstanding
Compared to 1 year ago, QURE has a worse debt to assets ratio.
QURE Yearly Shares OutstandingQURE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
QURE Yearly Total Debt VS Total AssetsQURE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -0.59, we must say that QURE is in the distress zone and has some risk of bankruptcy.
QURE has a Altman-Z score of -0.59. This is comparable to the rest of the industry: QURE outperforms 57.74% of its industry peers.
QURE has a Debt/Equity ratio of 2.26. This is a high value indicating a heavy dependency on external financing.
QURE has a Debt to Equity ratio of 2.26. This is in the lower half of the industry: QURE underperforms 78.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.26
Debt/FCF N/A
Altman-Z -0.59
ROIC/WACCN/A
WACC6.36%
QURE Yearly LT Debt VS Equity VS FCFQURE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

QURE has a Current Ratio of 7.12. This indicates that QURE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.12, QURE is in the better half of the industry, outperforming 70.19% of the companies in the same industry.
A Quick Ratio of 7.12 indicates that QURE has no problem at all paying its short term obligations.
QURE has a Quick ratio of 7.12. This is in the better half of the industry: QURE outperforms 70.75% of its industry peers.
Industry RankSector Rank
Current Ratio 7.12
Quick Ratio 7.12
QURE Yearly Current Assets VS Current LiabilitesQURE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

QURE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.11%, which is quite good.
QURE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -44.90%.
The Revenue has been growing by 30.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.65%
Revenue 1Y (TTM)-44.9%
Revenue growth 3Y-62.73%
Revenue growth 5Y30.01%
Sales Q2Q%61.83%

3.2 Future

QURE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.33% yearly.
Based on estimates for the next years, QURE will show a very strong growth in Revenue. The Revenue will grow by 75.98% on average per year.
EPS Next Y20.44%
EPS Next 2Y15.62%
EPS Next 3Y14.73%
EPS Next 5Y23.33%
Revenue Next Year-58.47%
Revenue Next 2Y2.59%
Revenue Next 3Y63.14%
Revenue Next 5Y75.98%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
QURE Yearly Revenue VS EstimatesQURE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
QURE Yearly EPS VS EstimatesQURE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

QURE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year QURE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QURE Price Earnings VS Forward Price EarningsQURE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QURE Per share dataQURE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

QURE's earnings are expected to grow with 14.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.62%
EPS Next 3Y14.73%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for QURE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

UNIQURE NV

NASDAQ:QURE (1/6/2026, 8:00:01 PM)

After market: 22.75 +0.44 (+1.97%)

22.31

-0.32 (-1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners91.11%
Inst Owner Change0%
Ins Owners1.48%
Ins Owner Change-0.23%
Market Cap1.39B
Revenue(TTM)15.75M
Net Income(TTM)-235.15M
Analysts81
Price Target54.25 (143.16%)
Short Float %15.35%
Short Ratio2.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.02%
Min EPS beat(2)-50.39%
Max EPS beat(2)24.35%
EPS beat(4)2
Avg EPS beat(4)-36.4%
Min EPS beat(4)-139.62%
Max EPS beat(4)24.35%
EPS beat(8)4
Avg EPS beat(8)-16.52%
EPS beat(12)5
Avg EPS beat(12)-30.89%
EPS beat(16)8
Avg EPS beat(16)-14%
Revenue beat(2)0
Avg Revenue beat(2)-20.37%
Min Revenue beat(2)-30.8%
Max Revenue beat(2)-9.94%
Revenue beat(4)0
Avg Revenue beat(4)-46.9%
Min Revenue beat(4)-75.51%
Max Revenue beat(4)-9.94%
Revenue beat(8)3
Avg Revenue beat(8)-18.19%
Revenue beat(12)4
Avg Revenue beat(12)-5.3%
Revenue beat(16)5
Avg Revenue beat(16)5.32%
PT rev (1m)-7.87%
PT rev (3m)-21.58%
EPS NQ rev (1m)-0.96%
EPS NQ rev (3m)-4.63%
EPS NY rev (1m)-1.36%
EPS NY rev (3m)-13.77%
Revenue NQ rev (1m)-11.8%
Revenue NQ rev (3m)-8.78%
Revenue NY rev (1m)-4.24%
Revenue NY rev (3m)-9.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 88.23
P/FCF N/A
P/OCF N/A
P/B 6.08
P/tB 10.75
EV/EBITDA N/A
EPS(TTM)-4.41
EYN/A
EPS(NY)-3.28
Fwd EYN/A
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-2.46
OCFYN/A
SpS0.25
BVpS3.67
TBVpS2.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.47%
ROE -102.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.13%
FCFM N/A
ROA(3y)-32.71%
ROA(5y)-18.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.17%
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 2.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.23%
Cap/Sales 2.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.12
Quick Ratio 7.12
Altman-Z -0.59
F-Score5
WACC6.36%
ROIC/WACCN/A
Cap/Depr(3y)98.33%
Cap/Depr(5y)124.6%
Cap/Sales(3y)24.73%
Cap/Sales(5y)20.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.65%
EPS Next Y20.44%
EPS Next 2Y15.62%
EPS Next 3Y14.73%
EPS Next 5Y23.33%
Revenue 1Y (TTM)-44.9%
Revenue growth 3Y-62.73%
Revenue growth 5Y30.01%
Sales Q2Q%61.83%
Revenue Next Year-58.47%
Revenue Next 2Y2.59%
Revenue Next 3Y63.14%
Revenue Next 5Y75.98%
EBIT growth 1Y7.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.83%
EBIT Next 3Y9.61%
EBIT Next 5Y33.52%
FCF growth 1Y4.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.42%
OCF growth 3YN/A
OCF growth 5YN/A

UNIQURE NV / QURE FAQ

Can you provide the ChartMill fundamental rating for UNIQURE NV?

ChartMill assigns a fundamental rating of 3 / 10 to QURE.


What is the valuation status for QURE stock?

ChartMill assigns a valuation rating of 0 / 10 to UNIQURE NV (QURE). This can be considered as Overvalued.


What is the profitability of QURE stock?

UNIQURE NV (QURE) has a profitability rating of 2 / 10.


How financially healthy is UNIQURE NV?

The financial health rating of UNIQURE NV (QURE) is 3 / 10.


What is the expected EPS growth for UNIQURE NV (QURE) stock?

The Earnings per Share (EPS) of UNIQURE NV (QURE) is expected to grow by 20.44% in the next year.